XML 71 R57.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Revenue Recognition - Performance Obligations - Additional Information (Details) $ in Millions |  | 1 Months Ended | 12 Months Ended
--- | --- | --- | ---
Jul. 27, 2020 Obligation | Oct. 31, 2023 USD ($) | Aug. 31, 2023 USD ($) | Aug. 31, 2022 USD ($) | Dec. 31, 2023 | Dec. 31, 2022 USD ($)
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] |  |  |  |  |  |
Reimbursement period of costs incurred for quarter ended |  |  |  |  | 75 days |
MAT2A Supply |  |  |  |  |  |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] |  |  |  |  |  |
Revenue recognized |  |  |  |  |  | $ 2.4
GSK |  |  |  |  |  |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] |  |  |  |  |  |
Reimbursement period of costs incurred for quarter ended |  |  |  |  | 75 days |
Revenue recognized |  |  |  |  |  | $ 17.4
GSK Collaboration Agreement |  |  |  |  |  |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] |  |  |  |  |  |
Number of performance obligations | Obligation | 6 |  |  |  |  |
Pol Theta Program |  |  |  |  |  |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] |  |  |  |  |  |
Milestone payment received clinical evaluation |  |  | $ 7.0 |  |  |
Milestone payment received for achievement of earlier preclinical development milestone |  |  | 3.0 | $ 3.0 |  |
Additional milestone payment potentially received clinical evaluation |  |  | $ 10.0 |  |  |
Reimbursement period of costs incurred for quarter ended |  |  |  |  | 90 days |
WRN Program |  |  |  |  |  |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] |  |  |  |  |  |
Milestone payment received clinical evaluation |  | $ 3.0 |  |  |  |
Milestone payment received for achievement of earlier preclinical development milestone |  | $ 3.0 |  |  |  |
Reimbursement period of costs incurred for quarter ended |  |  |  |  | 75 days |
Determination period of costs incurred |  |  |  |  | 75 days |

X
- Definition Additional milestone payment potentially received clinical evaluation + References No definition available. + Details
Name: | idya_AdditionalMilestonePaymentPotentiallyReceivedClinicalEvaluation
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The period to determine an amount of reimbursable costs. + References No definition available. + Details
Name: | idya_DeterminationPeriodOfCostsIncurred
Namespace Prefix: | idya_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone payment received clinical evaluation + References No definition available. + Details
Name: | idya_MilestonePaymentReceivedClinicalEvaluation
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Milestone payment received for achievement of initial preclinical development milestone. + References No definition available. + Details
Name: | idya_MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of performance obligations. + References No definition available. + Details
Name: | idya_NumberOfPerformanceObligations
Namespace Prefix: | idya_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Reimbursement period of costs incurred. + References No definition available. + Details
Name: | idya_ReimbursementPeriodOfCostsIncurred
Namespace Prefix: | idya_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=idya_MethionineAdenosylTransferase2AProgramSupplyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=idya_GlaxoSmithKlineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=idya_GlaxoSmithKlineCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=idya_PolymeraseThetaProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=idya_WernerHelicaseProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |